Close Menu

NEW YORK (GenomeWeb) – CareDx reported today that its first quarter revenues grew 76 percent year over year, amid growing sales of its AlloMap heart transplant test.

For the three months ended March 31, CareDx's revenues rose to $11.6 million from $6.6 million in the same period last year, topping analysts' consensus revenues estimate of $11.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.